NCT05954871View on ClinicalTrials.gov

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

January 8, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Colorectal CancerNon-Small Cell Lung Cancer
Interventions
DRUG

GDC-1971

GDC-1971 capsules or tablets will be administered as specified in each treatment arm.

DRUG

Osimertinib

Osimertinib tablets will be administered as specified in each treatment arm.

DRUG

Cetuximab

Cetuximab, solution for infusion will be administered as specified in each treatment arm.

Trial Locations (6)

3065

St Vincent's Hospital Melbourne, Fitzroy

3690

Border Medical Oncology, Wodonga

37203

SCRI Oncology Partners, Nashville

78229

START South Texas Accelerated Research Therapeutics-San Antonio, San Antonio

03080

Seoul National University Hospital, Seoul

05505

Asan Medical Center, Seoul

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY